BRÈVE

sur SCHOTT Pharma AG & Co. KGaA

SCHOTT Pharma Launches Large Format RTU Cartridges for On-Body Devices

SCHOTT Pharma has unveiled new 10ml ready-to-use (RTU) cartridges designed to store biologics used for treating conditions like cancer, metabolic and cardiovascular disorders, genetic issues, and immunological diseases. The introduction aims to ease subcutaneous self-injection for patients, enabling home administration and reducing healthcare costs.

The large format RTU cartridges are compatible with Ypsomed’s YpsoDose on-body device. The system is the first of its kind to be prefilled and pre-loaded, reducing handling steps for end-users. SCHOTT Pharma's CEO, Andreas Reisse, emphasized the transition from intravenous to subcutaneous administration, enhancing patient convenience.

Currently, about 80% of the 6,200 injectable drugs in development are biologics. These new RTU cartridges provide a reliable solution for storing and administering these complex drugs. Reto Jost from Ypsomed highlighted the collaboration's focus on patient needs and accelerating time-to-market for new treatments.

The cartriQ® RTU cartridges use in-house steam sterilization to ensure sterility and sustainability. They also feature a sterile barrier integrated into the crimp cap, eliminating manual swabbing. This innovation supports SCHOTT Pharma’s strategic shift towards high-value solutions and sustainability goals.

R. H.

Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.

Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève

Voir toutes les actualités de SCHOTT Pharma AG & Co. KGaA